Methods of using human tissue factor-producing knock-in mice

Details Methods of using human tissue factor-producing knock-in mice Methods of using human tissue factor-producing knock-in mice

2009-08-12

2011-11-29

Ton, Thaian N (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Method of using a transgenic nonhuman animal to manufacture...

The protein is isolated or extracted from blood or serum

C800S004000, C800S005000

Reexamination Certificate

active

08067665

ABSTRACT:
A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.

REFERENCES:
patent: 6703494 (2004-03-01), Kirchhofer et al.
patent: 2 388 408 (2001-04-01), None
Denning and Priddle. Reproduction, 126:1-11, 2003.
Cao et al. J. of Exp. Zoo., 311A: 368-376, 2009.
Brevini et al. Theriogenology, 74: 544-550, 2010.
Paris et al. Theriogenology, 74: 516-524, 2010.
Clark et al. Nature Reviews: 4: 825-833, 2003.
Barthold, Stephen W., “Genetically altered mice: Phenotypes, no phenotypes, and Faux phenotypes,” Genetica, 2004, 122:75-88.
Bromberg et al., “Role of Tissue Factor in Metastasis: Functions of the Cytoplasmic and Extracellular Domains of the Molecule”, Thrombosis and Haemostasis, vol. 82, 1999, pp. 88-92.
Cameron, Ewan R., “Recent Advances in Transgenic Technology,” Molecular Biotechnology, 1997, 7:253-265.
Declerck et al., “Generation of Monoclonal Antibodies against Autologous Proteins in Gene-inactivated Mice”, The Journal of Biological Chemistry, Apr. 1995, pp. 8397-8400, vol. 270-No. 15.
Erlich et al., “Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation”, Proc. Natl., Acad, Sci. USA, Jul. 1999, pp. 8138-8143, vol. 96.
Erlich et al., “Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation,” Proc. Natl. Acad. Sci. USA, Jul. 1999, 96:8138-8143.
Gerlai, Robert, “Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?”, Trends in Neuroscience, 1996, 19(5):177-181.
Holschneider et al., “Genotype to phenotype: challenges and opportunities,” Int. J. Devl. Neuroscience, 2000, 18:615-618.
Houdebine, Louis-Marie, “Production of pharmaceutical proteins from transgenic animals,” Journal of Biotechnology, 1994, 34:269-287.
Kappel et al., “Regulating gene expression in transgenic animals,” Current Opinion in Biotechnology, 1992, 3:548-553.
Lariviere et al., “Transgenic Studies of Pain and Analgesia: Mutation or Background Genotype?”, Journal of Pharmacology and Experimental Therapeutics, 2001, 297(2):467-473.
Mackman et al., “Complete Sequence of the Human Tissue Factor Gene, a Highly Regulated Cellular Receptor That Initiates the Coagulation Protease Cascade,” Biochemistry, 1989, 28:1755-1762.
Mackman et al., “Structure of the Murine Tissue Factor Gene”, Arterosclerosis and Thrombosis, Apr. 1992, pp. 474-483, vol. 12-No. 4.
Melis et al., “Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain”, Biochemical and Biophysical Research Communications, vol. 333, No. 2, Jul. 29, 2005, pp. 488-495.
Moreadith et al., “Gene targeting in embryonic stem cells: the new physiology and metabolism,” J. Mol. Med., 1997, 75:208-216.
Mullins et al., “Perspectives Series: Molecular Medicine in Genetically Engineered Animals,” J. Clin. Invest., 1996, 97:1557-1560.
Mullins et al., “Transgenesis in Nonmurine Species,” Hypertension, 1993, 22:630-633.
Niemann, “Transgenic farm animals get off the ground,” Transg. Res., 1998, 7:73-75.
Parry et al., “Low Levels of Tissue Factor Are Compatible with Development and Hemostasis in Mice”, The Journal of Clinical Investigation, Feb. 1998, pp. 560-569, vol. 101-No. 3.
Parry et al., “Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain”, The Journal of Clinical Investigation, Jun. 2000, pp. 1547-1554, vol. 105-No. 11.
Pearson, Helen, “Surviving a knockout blow,” Nature, Jan. 3, 2002, 415:8-9.
Pera et al., “Human embryonic stem cells,” Journal of Cell Science, 2000, 113:5-10.
Sato, “Gene Trap, Gene Knockout, Gene Knock-In, and Transgenics in Vascular Development”, Thrombosis and Haemostasis, Aug. 1999, pp. 865-869, vol. 82-No. 2.
Seong et al., “To knockout in 129 or in C57BL/6: that is the question,” Trends in Genetics, Feb. 2004, 20(2):59-62.
Sigmund, Curt D., “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?”, Arteroscler. Throm. Vasc. Biol., 2000, 20:1425-1429.
Taylor et al., “LethalE. coliSeptic Shock is Prevented by Blocking Tissue Factor With Monoclonal Antibody”, Circulatory Shock, vol. 33, No. 3, 1991, pgs. 127-134.

Affiliated with

Also associated with

Rating

Methods of using human tissue factor-producing knock-in mice does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using human tissue factor-producing knock-in mice, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using human tissue factor-producing knock-in mice will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4253198